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1. Introduction  
The human gastrointestinal (GI) microbiota is a rich and dynamic community inhabited by 
approximately 1014 bacteria, most of which have not yet been cultivated in the laboratory 
(Zoetendal et al, 2006). The GI microbiota has been suggested as one of the etiological factors 
in irritable bowel syndrome (IBS), with a putative role in the development and maintenance 
of IBS symptoms (for a review, see Bolino & Bercik, 2010). The worldwide prevalence of IBS 
is 10-20% among adults and adolescents, depending on the diagnostic criteria applied 
(Longstreth et al, 2006). Abdominal pain or discomfort, irregular bowel movements and 
constipation or diarrhoea are common symptoms of IBS. Symptoms outside the GI tract, 
such as fatigue, anxiety and depression, are also often encountered. At its worst, IBS can 
cause significant effects on patients’ well-being, but it is not known to predispose to any 
severe illnesses. Patients can be grouped into three subtypes according to bowel habits: 
diarrhoea-predominant (IBS-D), constipation-predominant (IBS-C) or mixed-subtype (IBS-
M). However, the symptom subtype of each patient may vary over time (Longstreth et al, 
2006). 
Compared to non-IBS controls, subjects with IBS have been associated with a greater 
temporal instability of the GI microbiota and quantitative changes have been detected 
within several distinct bacterial groups or species-like phylotypes, which are defined based 
solely on sequence data (see Table 1 for references). In analyses covering the overall 
microbial community, IBS subjects have shown a tendency to cluster apart from the healthy 
control subjects (Ponnusamy et al, 2011; Rajilić-Stojanović, 2007). Moreover, the IBS 
symptom-subgroups IBS have been proposed to differ from each other according to the GI 
microbiota of subjects within these groups (Lyra et al, 2009; Malinen et al, 2005; Rajilic-
Stojanovic, 2007). The most distinctive symptom sub-type is IBS-D, which could also be a 
result of the impact of the diarrhoea on the microbial environment in the gut. In addition, 
comparatively low quantities of bifidobacteria, which are generally considered beneficial to 
health, have been detected in several IBS studies (Balsari et al, 1982; Enck et al, 2009; 
Kerckhoffs et al, 2009; Krogius-Kurikka et al, 2009; Si et al, 2004). This finding, though still 
preliminary, encourages development of probiotic and prebiotic therapies for IBS. On the 
other hand, elevated numbers of Proteobacteria and Firmicutes, including Ruminococcus –
like phylotypes, Lactobacillus sp. and Veillonella sp., have been reported. 
Quantitative and qualitative microbial alterations in the GI tract of IBS subjects may have a 
functional role in the syndrome aetiology or merely reflect the status of the gut, but still 
have diagnostic or prognostic value in clinical practise and research (Kassinen, 2009; 
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Salonen et al, 2010). In the following chapter, these IBS-related alterations within the human 
GI microbiota are reviewed. 
2. Intestinal microbiota 
The intestinal microbiota is individual-specific and relatively stable through time (Zoetendal 
et al, 1998). From a microbial point of view, a tremendous variety of physiologically 
connected environments exists in the human GI tract. The mouth and stomach harbour their 
distinct microbiotas (Bik et al, 2006; Zaura et al, 2009). In the small intestine, the bacterial 
load and diversity rise from 104 to 108 cells per millilitre of intestinal content towards the 
distal ileum. Veillonella, Streptococcus, Clostridium cluster I and Enterococcus form the core 
genera of the small intestinal lumen (Booijink et al, 2010). Reaching the colon, the transit 
slows down and the bacterial density rises from 108 in the caecum and ascending colon to an 
average of 1011 to 1012 cells of bacteria per gram in faeces. The proportion of obligate 
anaerobic bacteria expands to 99%. The phyla Firmicutes, Bacteroidetes, Actinobacteria, 
Proteobacteria, Fusobacteria and Verrucomicrobia are present in the colon (Andersson et al, 
2008; Kurokawa et al, 2007). In the small and large intestines, the mucosal and luminal 
microbiotas are distinct from each other (Booijink et al, 2007; Zoetendal et al, 2002). Recently 
it has been shown that the human GI microbiota roughly groups into three entorotypes, 
with either Bacteroides, Prevotella or Ruminococcus predominating (Arumugam et al, 2011).  
The GI microbiota has a dynamic mutualistic relationship with its host affecting host 
nutrition and metabolism, immunocompetence and tolerance, GI tract surface maturation 
and function and even behaviour, thus possessing a potentially tremendous impact on host 
well-being (for review see Sekirov et al, 2010). Multiple theories linking IBS aetiology with 
the intestinal microbiota have been proposed, which, together with the discovered IBS-
associated GI microbiota alterations, imply that bacteria may well play a role in IBS 
aetiology. 
3. Gut microbiota in IBS 
Alterations in the GI microbiota related to IBS have been investigated since the early 1980s’ 
by conventional culture-based methods and an array of molecular methods (Table 1). 
Several of the published studies are based on the same Finnish sample panel originating 
from a probiotic intervention and additional healthy control subjects. For clarity, these 
studies are represented under a separate sub-heading in Table 1. Besides differing from 
control subjects, IBS also differs from IBD including Crohn’s disease and ulcerative colitis 
(Enck et al, 2009; Ponnusamy et al, 2011). 
 
Study Samples Method Outcome for IBS1 subjects 
Balsari et al, 1982 20 IBS, 20 
Controls 
Culturing Less coliforms, lactobacilli and 
bifidobacteria  
Si et al, 2004 25 IBS, 25 
Controls 
Culturing Less bifidobacteia  
More Enterobacteriaceae  
Rajilić-
Stojanović, 2007 
20 IBS, 20 
Controls 
HITChip  Distinctive clustering; Subtype-
specific alterations; Higher inter-
individual variation 
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Kerckhoffs  
et al, 2009 
41 IBS 
26 Controls 
FISH, qPCR; Fecal 
and mucosal 
brush samples 
Bifidobacteria in feces and 
Bifidobacterium catenulatum  on the 
mucosa decreased 
Enck et al, 2009 7765 IBS, 198 CD, 
515 UC, 10478 
Other GI  diag. 
Culturing Less bifidobacteria than in samples 
of subjects with other GI 
complaints 
Malinen  
et al, 2010 
44 IBS qPCR, 
Questionnaires 
Previously IBS associated 
phylotype now associated with  
sensation of symptoms 
Codling  
et al, 2010 
47 IBS, 33 
Controls 
DGGE; Fecal and 
mucosal samples 
Lower inter-individual variation 
Tana et al, 2010 26 IBS, 26 
Controls 
qPCR, culturing, 
SCFA, 
questionnaires, 
X-ray 
Veillonella and lactobacilli 
elevated; Acetic, propionic and 
total SCFA elevated and correlated 
with symptoms  
Noor et al, 2010 11 IBS, 13 UC, 22 
Controls 
DGGE Less diversity among Bacteroides  
Carroll et al, 2010 10 IBS-D, 10 
Controls 
Culturing, qPCR;
Fecal and mucosal 
biopsy samples 
Less aerobes and more lactobacilli 
in feces 
Carroll et al, 2011 16 IBS-D, 21 
Controls 
T-RFLP; Fecal and 
mucosal biopsy 
samples 
The microbial profiles grouped 
according to origin (mucosal or 
luminal) rather than health status. 
Microbial composition at both 
mucosa and lumen altered in IBS-D. 
Ponnusamy  
et al, 2011 
11 IBS, 8 non-IBS 
patients 
DGGE, qPCR  Higher diversity  of total bacteria, 
Bacteroides and Lactobacillus; 
Elevated amino acids and phenolic 
compounds 
Saulnier  
et al, 2011 
22 Pediatric IBS, 
22 Control 
children 
Pyrosequencing, 
PhyloChip 
Gammaproteobacteria including 
Haemophilus influenzae elevated; 
Ruminococcus –like phylotype 
associated with IBS; Allistipes 
correlated with pain 
Studies on a Finnish sample set2 
Study / Method Healthy controls IBS subjects on placebo IBS subjects on 
probiotic3
Kajander  
et al., 2005; 
Intervention 
NA Analysed as control Total symptom score 
reduced (borborygmi) 
Malinen  
et al., 2005;  
qPCR 300 gut 
species 
Analyzed as control High Lactobacillus sp. in 
IBS-D 
LowVeillonella sp. in IBS-
C  
NA 
Mättö et al., 2005; 
Culturing, DGGE
Analysed as control More coliforms;  Higher 
aerobe:anaerobe ratio 
NA 
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Maukonen  
et al., 2006; 
DGGE, TRAC,  
Analysed as control Less Clostridium 
coccoides-Eubacterium 
rectale in IBS-C (RNA); 
Less stable microbiota 
(RNA) 
NA 
Kajander  
et al., 2007; qPCR 
300 gut species 
NA Analyzed as control No alteration 
Kassinen  
et al., 2007; 
G+C%, 
sequencing, 
qPCR 
Analyzed as control Altered community 
structure; 
3  altering phylotypes  
NA 
Lyra et al., 2009; 
qPCR 14 
phylotypes 
Two associated 
phylotypes 
IBS-D and IBS-C 
associated phylotypes; 
IBS-D distinguishable  
NA 
Krogius-Kurikka 
et al., 2009; 
G+C%, 
sequencing 
Actinobacteria 
abundant 
NA NA 
Krogius-Kurikka 
et al., 2009; 
G+C%, 
sequencing, 
qPCR 
More  
Actinobacteria and 
Bacteroidetes 
IBS-D enriched with 
Proteobacteria and 
Firmicutes, especially 
Lachnospiraceae  
NA 
Lyra et al., 2010; 
qPCR 8 
phylotypes 
NA Analyzed as control Quantities shifted 
towards healthy like 
levels 
Rinttilä  
et al., 2011; qPCR 
12 pathogens 
Analyzed as control Staphylococcus aureus 
more prevalent in IBS  
NA 
1The abbreviations in order of appearance stand for IBS, irritable bowel syndrome; HITCip, Human 
Intestinal Tract Chip; FISH, fluorescent in situ hybridization; qPCR, real-time quantitative PCR; CD, 
Crohn’s disease; UC, ulcerative colitis; GI, gastrointestinal; DGGE, denaturing gradient gel 
electrophoresis; SCFA, short chain fatty acids; IBS-D, diarrhea-predominant IBS; T-RFLP, terminal-
restriction fragment length polymorphism; NA, not analyzed; and IBS-C, constipation-predominant IBS. 
2The sample set consisted of probiotic intervention samples from the intervnetion by Kajander et al., 
(2005) and additional control samples from subjects devoid of gastrointestinal symptoms. The detected 
alterations are given under the sample group they apply to. 
3The probiotic supplement was a combination of L. rhamnosus GG and Lc705, B. breve Bb99 and P. 
freudenreichii ssp. shermanii JS administered for 6 months at a daily dose of 8–9 x 109 CFU with equal 
amounts of each strain (Kajander et al, 2005). 
Table 1. Studies on irritable bowel syndrome (IBS) related intestinal microbiota.  
3.1 Culture-based analyses 
Using culture-based techniques, the GI microbiota of IBS patients was characterized as 
having less coliforms, lactobacilli and bifidobacteria in a study with 20 IBS patients and 20 
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controls (Balsari et al, 1982). Likewise, in a later study (Si et al, 2004) with 25 IBS patients 
fulfilling the Rome II criteria and 25 controls, lower levels of bifidobacteria were detected in 
IBS patients, but the level of bacteria belonging to the family Enterobacteriaceae was higher in 
IBS patients. Contrary to Balsari et al. (1982), Mättö et al. (2005) detected more coliforms in 
IBS subjects’ and no difference in the bifidobacterial counts using culture-based methods, 
whereas the number of coliforms and aerobe:anaerobe ratio were elevated (26 IBS and 25 
control subjects). In 2009, Enck and colleagues conducted an impressive culturing study by 
analysing the intestinal microbiota of a total of 34 313 subjects of varying conditions (Enck et 
al, 2009). Routine analyses were applied to Clostridium difficile, Bifidobacterium spp., 
Bacteroides spp., Escherichia coli, Enterococcus spp. and Lactobacillus spp. A total of 7 765 IBS 
subjects were included in the final data analysis revealing a significantly lower abundance 
of Bifidobaterium spp. In the latest study based on culturing, aerobes were elevated in the 
faecal samples of IBS-D patients compared with control subjects, whereas anaerobes, 
Clostridium spp., Bacteroides spp., Lactobacillus spp., Bifidobacterium spp., and Escherichia coli 
were not altered in IBS-D (Carroll et al, 2010). 
Taken together, evidence for increased numbers of aerobes and comparably low counts of 
bifidobacteria exist from culture based analyses with the latter giving good grounds for 
prebiotic and probiotic therapy research. The results on coliforms are contradictory between 
different studies. 
3.2 Community structure with molecular methods 
The overall microbial community from faecal samples of IBS subjects has been analysed 
applying denaturing gradient gel electrophoresis (DGGE), microarray (HITCip and 
PhyloChip), and sequencing (conventional Sanger sequencing and 2nd generation 454 
pyrosequencing). All of these methods are capable of detecting the unculturable species in 
the microbiota, although they bear restrictions due to primer and probe dependency and 
technical biases. The main advantage is the possibility to gain a non-restricted overview and 
with sequencing, to able to design targeted primers and probes for applications based on 
PCR or hybridization. 
Greater temporal instability of the intestinal microbiota of IBS patients compared with that 
of healthy controls has been detected with RNA-based DGGE (Maukonen et al, 2006). 
Applying DNA-based DGGE on the same sample set did not show IBS related temporal 
variation (Maukonen et al, 2006), but variation due to antibiotic therapy was observed 
(Mättö et al, 2005). The inter-individual variability has been assessed in two studies with 
contradictory results. With the HITChip microarray analysis IBS subjects showed 
significantly more inter-individual variation compared with the controls (Rajilić-Stojanović, 
2007), whereas with DGGE more variation was seen amongst control subjects (Codling et al, 
2010). This discrepancy is likely due to methodological differences as the probe or primer 
based bacterial targets differ. 
Moreover, the biodiversity, an expression of species richness and abundance, is decreased in 
IBS (Noor et al, 2010). Loss of species richness was especially evident among Bacteroides species, 
which was speculated to suggest their putative protective role in the GI tract (Noor et al, 2010). 
Krogius-Kurikka et al. (2009) also found IBS-D related GI microbiota to lack diversity in a 
sequencing analysis, but the number of samples pooled prior to analysis was lower in the IBS-
D sample possibly affecting the result (Krogius-Kurikka et al, 2009). On the other hand, 
Saulnier and colleagues (2011) analysed multiple samples from 22 pediatric IBS patients and 22 
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control subjects with 454 pyrosequencing (54 287 reads per sample) and a portion of the 
samples further with the PhyloChip which targets revealing no significant difference in 
bacterial bacterial quantities or richness, although qualitative changes were detected between 
the two subject groups and in relation to perception of pain (Saulnier et al, 2011). 
Thus, at least for adult IBS subjects, the diversity and species richness in the GI microbiota 
are diminished, which would together with the alternating symptoms explain a higher 
temporal and inter-individual variation in the gut microbiota. A less stable microbiota is 
potentially more vulnerable to external interference (infection, antibiotics, stress), possibly 
leading to a recurrent aberration in gut function. 
3.3 From community to phylotype level 
In addition to the overall community structure and stability in the GI tract, the thousands of 
bacterial species therein, referred to as phylotypes when based only on molecular data, are 
important. Aspects such as their absolute and relative abundance, prevalence and 
association to symptoms sub-types and perception have been studied.  
The sample set studied by Mättö et al. (2005) and Maukonen et al. (2006) was further studied 
using 20 quantitative real-time PCR (qPCR) assays covering approximately 300 bacterial 
species (27 IBS patients and 22 controls gave faecal samples at the first time-point; 21 IBS 
patients and 15 controls gave faecal samples at three time-points at three-month intervals) 
(Malinen et al, 2005). The first time-point was analysed with IBS subjects divided into 
symptom subgroups; IBS-D, IBS-C and IBS-M. Statistically significant differences were 
observed with real-time PCR assays targeting Lactobacillus spp. (less abundant in IBS-D than 
in IBS-C), Veillonella spp. (less abundant in controls than in IBS-C) and Bifidobacterium spp. 
(less abundant in IBS-D than in all other groups). The Clostridium coccoides and 
Bifidobacterium catenulatum group assays detected more target bacteria in controls than in IBS 
patients when the results from the three different time-points were averaged and the IBS 
subjects analysed as a single group. 
Thereafter, the samples were analysed with percent guanine plus cytosine (%G+C) profiling 
(Kassinen et al, 2007): The pooled symptom subtype profiles diverged with the %G+C 
profiling and the three most diverging fractions were subsequently studied using 16S rDNA 
Sanger sequencing. Real-time PCR assays targeting specifically the alterations between the 
sequesnce libraries of IBS and control subjects were designed and applied in several studies 
highlighting a ruminococcal phylotype in relation to IBS-D and a taxonomically 
unclassifiable phylotype with the control subjects and IBS subjects under probiotic theraphy 
(Lyra et al, 2010; Lyra et al, 2009; Malinen et al, 2010). 
Ruminococcal bacteria have also been associated with Crohn’s disease and pediatric IBS 
(Frank et al, 2007; Martinez-Medina et al, 2006; Saulnier et al, 2011). Ruminococci include 
mucolytic bacteria with a possible competitive advantage in a disturbed gut with excessive 
mucus secretion. Novel uncultured bacterial phylotypes discovered in relation to IBS and 
health may also perform well as diagnostic microbiome signatures (Kassinen et al, 2007; 
Lyra et al, 2009; Saulnier et al, 2011) although their possible relation to the syndrome is mere 
speculation at this stage. The genera Bifidobacterium, Coriobacterium and Collinsella within the 
phylum Actinobacteria have been less abundant in IBS patients (Enck et al, 2009; Kassinen et 
al, 2007; Kerckhoffs et al, 2009; Lyra et al, 2009). Correspondingly, redused levels of 
Actinobacteria including bifidobacteria have been associated with Crohn’s disease patients 
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(Fyderek et al, 2009; Manichanh et al, 2006; Sokol et al, 2009), and Collinsella aerofaciens has 
been associated with a low risk of colon cancer (Moore & Moore, 1995). 
These more specific changes, once well established in relation to both healthy and non-IBS 
GI patient controls, have potential in diagnostics and tailor-made therapeutic approaches. 
The possibility of finding a causative agent for IBS, for instance among the ruminococcal 
phylotypes, is intriguing though still a future challenge. 
3.4 Microarray analyses 
Two 16S rRNA gene sequence based microarrays with a wide array of target phylotypes 
have been applied to IBS samples. The advantage of microarrays is their semi-quantitative 
nature, high-throughput capability and more straightforward applicability to diagnostic and 
therapeutic applications.  
The first microarray analysis focusing on IBS-associated GI microbiota applying a 
microarray (The Human Intestinal Tract Chip, HITChip) was published in 2007 (Rajilic-
Stojanovic, 2007). The HITChip is a 16S rRNA gene-based phylogenetic microarray 
specifically designed to target the human intestinal microbiota (Rajilic-Stojanovic et al, 2009). 
It is unable to quantify phylotypes directly, but relative changes in hybridization signals can 
be detected between 0.1% and 3% subpopulations in an artificial mixture of 30 phylotypes 
(Rajilic-Stojanovic, 2007). The HITChip study on IBS encompassed 20 IBS patients sub-
grouped according to symptom subtype and 20 healthy controls. With a hierarchical cluster 
analysis, the phylogenetic fingerprints of the faecal microbiota of IBS patients and controls 
grouped into two distinctive groups, with one dominated by IBS patients’ samples (14 IBS 
patients and 4 controls) and the other by healthy controls’ samples (16 controls and 6 IBS 
patients). The clustering did not correlate with the IBS symptom subtype. Stronger variation 
in the composition of the microbiota was seen among the IBS patients’ profiles. 
Within the phylotypes targeted by the HITChip, the IBS-C group of IBS patients had lower 
levels of Bacteroides species (Bacteroides ovatus, Bacteroides uniformis, Bacteroides vulgatus) and 
Clostridium stercorarium-like bacteria and higher levels of Bacillus spp.; the IBS-D patients 
were characterized by higher levels of Aneuribacillus spp., Streptococcus mitis and 
Streptococcus intermedius-like bacterial phylotypes from the order Bacilli. Various IBS-
subgroup dependent differences were detected within Clostridium cluster XIVa (C. coccoides 
group). For instance, Roseburia intestinalis was more abundant in IBS-D and Ruminococcus 
gnavus in alternating-type IBS than in healthy controls. Several phylotypes within the 
Clostridium cluster IV (the Clostridium leptum –group) were more prominent in IBS-C than in 
IBS-D. (Rajilic-Stojanovic, 2007) 
The other microarray analysis was done on pediatric IBS subjects applying the PhyloChip 
(Saulnier et al, 2011). PhyloChip targets a wider array of microbes not specifically restricted 
to the expected human intestinal tract inhabitants (Brodie et al, 2006) although it is well 
applicable also to analysing intestinal microbiota (Nelson et al, 2011; Saulnier et al, 2011). 
Saulnier and colleagues (2011) discovered that Proteobacteria, especially 
Gammaproteobacteria, are abundant in pediatric IBS subjects. Within these 
Gammaproteobacteria the species Haemophilus parainfluenzae was commonly encountered. 
Similarly the pyrosequencing analysis revealed elevated numbers of Protebacteria and 
unclassified ruminococcal phylotypes in association to pediatric IBS and (Saulnier et al, 
2011). In the PhyloChip analysis, several Bacteroides phylotypes, including a Bacteroides 
vulgatus –like phylotype, were elevated in healthy children (Saulnier et al, 2011), as has 
www.intechopen.com
 
Current Concepts in Colonic Disorders 
 
268 
previously been noted in the case of adult subjects with ulcerative colitis (UC) or IBS (Noor 
et al, 2010). 
These efficient high-throughput methods have potential for analyzing large enough sample 
sets to identify common alterations in the heterogeneous IBS subject population. So far too 
few studies have been published for making a consensus on the results. In addition, it 
would be beneficial if the sampling schema would include several samples linked to 
thorough symptom data from each subject as both the microbiota and the symptoms in IBS 
are prone to alter over time. 
3.5 The mucosal microbiota 
The mucosal microbiota is of special interest in health related studies as it is in an intimate 
contact with the host. In a healthy intestine, the mucosal microbiota resides on the mucosal 
lining of the epithelium, whereas in a damaged intestine straight contact with the host 
epithelium is plausible. Fluorescent in situ hybridization (FISH) applied on mucosal 
samples of patients with IBD, IBS or no GI symptoms revealed that mucosal bacteria were 
more abundant in IBS patients than in healthy controls, although the difference was less 
evident than with the IBD patients (Swidsinski et al, 2005). The proportional amounts of the 
different bacterial groups targeted in the FISH analysis (Bacteroides-Prevotella, Bacteroides 
fragilis, Eubacterium rectale-Clostridium coccoides, Faecalibacterium prausnitzii and Enterococcus 
faecalis), however, were similar between IBS patients and controls (Swidsinski et al, 2005). 
Likewise, Carroll and colleagues (2010) found no significant difference between the 
abundances of cultured bacteria (aerobic, anaerobes, Clostridium spp., Bacteroides spp., 
Lactobacillus spp., Bifidobacterium spp., and Escherichia coli). With qPCR, elevated levels of 
Pseudomonas aeruginosa, a gram-negative opportunistic pathogen, have been detected in 
duodenal brush samples of IBS patients. Nevertheless, a recent terminal-restriction fragment 
length polymorphism (T-RFLP) analysis was able to differentiate between the composition 
of IBS-D patients’ and control subjects’ mucosal microbiota, although the overall microbial 
profiles clustered according to site of sampling (mucosal or luminal) rather than health 
status (IBS-D or healthy control) (Carroll et al, 2011). 
Taken together, no drastic alteration in the mucosal microbiota of IBS subjects has been 
defined. The mucosal and luminal microbiotas differ in IBS subjects as they do in healthy 
controls, underlying the importance of research on this specific niche. One reason for the 
small number of mucosal IBS studies is the invasive nature of mucosal sampling as 
colonoscopy is not a regular procedure in IBS diagnostics or treatment.  
4. Microbial metabolites and enzymes 
4.1 Short Chain Fatty Acids (SCFAs) 
The principal products of microbial carbohydrate metabolism in the human GI tract are 
short-chain fatty acids (SCFAs), which can be absorbed by the human host. The SCFAs 
produced throughout the GI tract are mainly acetate, butyrate and propionate, but in the 
colon acetate predominates (Cummings et al, 1987). The colonic epithelial cells prefers 
butyrate over other SCFAs as an energy source, and butyrate has been shown to have a 
positive effect on health (Pryde et al, 2002). The most abundant intestinal butyrate-
producing bacteria are Firmicutes from Clostridial clusters XIVa and IV (Clostridium, 
Eubacterium, Fusobacterium) (Pryde et al, 2002). Starch fermentation by starch-degrading 
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bacteria results in comparatively high amounts of butyrate (Chassard et al, 2008). Starch-
degrading bacteria, including Ruminococcus bromii (Clostridium cluster IV), Eubacterium 
rectale (Clostridium cluster XIVa) and bifidobacteria (Leitch et al, 2007), comprise 
approximately 10% of culturable bacteria in faecal samples (Chassard et al, 2008). 
Reduced amounts of total SCFAs due to lower levels of acetate and propionate have been 
measured in association with IBS-D, while an elevated concentration of n-butyrate seemed 
to be characteristic of IBS-D (Treem et al, 1996). Tana and colleagues (2010) analysed the 
microbiota and SCFAs from faecal samples donated by 26 IBS and 26 control subjects. 
Contrary to Treem et al. (1996), the IBS subjects had elevated numbers of Veillonella spp. and 
Lactobacillus spp. together with higher concentrations of total organic acids and acetic and 
propionic acid. The increase in acidic metabolites was more pronounced in the group of IBS 
subjects with worse GI symptoms, quality of life and emotional status according to 
subjective evaluation (Tana et al, 2010). 
Colonic gas production (H2 and CH4) has been shown to be greater in patients with IBS 
(Rome II criteria) compared with controls using a standardized diet, which might be 
associated with alterations in the activity of hydrogen-consuming bacteria (King et al, 1998). 
An exclusion diet, mainly devoid of dairy products and cereals other than rice, reduced IBS 
symptoms and lowered the maximum gas excretion (King et al, 1998). Furthermore, 
functional constipation and IBS-C have been associated with methane production according 
to breath testing in a recent meta-analysis (Kunkel et al, 2011). 
Thus, although the results on microbial metabolites in the colon are still scarce and to some 
extent contradictory, they have been linked to symptom severity and defecation habit sub-
type. The elevated amount of butyrate among IBS-D subjects in one study is surprising, as 
butyrate is considered to have a positive effect on health. 
4.2 Luminal proteases 
Certain studies have suggested an association between luminal proteases and IBS. An 
elevated faecal serine protease activity has been associated with IBS-D (Roka et al, 2007). The 
faecal supernatants from IBS-D patients caused increased colonic paracellular permeability 
when administered to the mucosal side of a mouse colon strip and increased visceral 
hypersensitivity in mice (Gecse et al, 2008). Gecse et al. (2008) also showed that the effect on 
mucosal permeability is mediated by serine protease through protease-activated receptor 
two (PAR-2). Pre-incubation with serine protease inhibitors decreased the effect of the faecal 
supernatant from the IBS-D patients on the colonic paracellular permeability of mouse colon 
strips. Furthermore, the use of colonic strips derived from PAR-2-deficient mice completely 
removed the increase in colonic paracellular permeability. The elevated serine protease 
activity in IBS-D patients was suggested to be of microbial origin (Gecse et al, 2008). The 
PAR-2 mediated increase in visceral hypersensitivity appears to be specifically related to 
IBS-D in comparison to inflammatory bowel diseases (IBD) (Annahazi et al, 2009). 
The evidence for the role of luminal proteases in IBS symptoms is at its early stage, but 
intriguing. It links the GI microbiota with the host’s IBS symptoms through increased gut 
permeability and visceral hypersensitivity. 
5. Post-infectious IBS 
In a large cohort study (over 500 000 patients), gastroenteritis was concluded to increase the 
risk of developing IBS by a factor of ten (Rodriguez & Ruigomez, 1999). Post-infectious IBS 
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(PI-IBS) has been reported after Campylobacter, Shigella and Salmonella infections (Ji et al, 
2005; Mearin et al, 2005; Spiller et al, 2000) and Staphylococcus aureus has been detected in a 
comparatively high prevalence in IBS subjects (Rinttilä et al, 2011). Nevertheless, PI-IBS 
appears to be a non-specific response (Spiller, 2007). Typically PI-IBS is characterized by 
loose stools, less depression and anxiety and increased enterochromaffin cells in mucosal 
biopsies compared with non-PI-IBS (Dunlop et al, 2003; Neal et al, 2002). Detecting an 
infectious agent from random IBS subjects is unlikely (Rinttilä et al, 2011), but this still does 
not rule out the possibility of an earlier infectious event having etiological importance. 
Since the initial gastroenteritis triggering PI-IBS is a coincidental event, and among PI-IBS 
patients the symptoms are relatively homogeneous and psychological abnormalities are less 
common than in other IBS patients, PI-IBS presents a clearer model for studying the possible 
mechanisms underlying IBS (Spiller, 2007). On the other hand, PI-IBS may be etiologically 
too distinct to represent the whole of IBS subtype variety.  
In addition to acute gastroenteritis triggering IBS symptomology, low-grade inflammation 
with focus on mast cells and monocytes has been suggested to have a pivotal role in IBS 
aetiology (for review see Ohman & Simren, 2010). Low-grade mucosal inflammation 
(Barbara et al, 2007; Chadwick et al, 2002; Dunlop et al, 2003; Ohman et al, 2005) and stable 
alterations in mucosal gene expression (Aerssens et al, 2008) of IBS patients of all symptom 
subtypes have been detected. Furthermore, the basal and E. coli lipopolysaccharide induced 
release of pro-inflammatory cytokines from peripheral blood mononuclear cells has been 
shown to be elevated in IBS-D patients compared to healthy controls (Liebregts et al, 2007). 
Additionally, antibodies against certain bacterial flagellin have been detected in IBS 
patients, particularly in PI-IBS patients, with a higher frequency than in healthy controls 
(Schoepfer et al, 2008). 
Taken together, PI-IBS is a widely accepted sub-type of IBS which can reside from a variety 
of causative agents. Minimizing risk, severity and length of acute gastroenteritis would 
likely lower the risk of recurrent functional GI disturbances such as IBS. 
6. Probiotics for balancing the GI microbiota in IBS 
Being a syndrome diagnosed based on subjective assessment of GI function, the most 
important outcome in IBS intervention studies is the patients’ sensation of symptom relief. 
This is usually assessed by applying GI symptom questionnaires. According to a recent 
meta-analysis, the separate IBS symptoms (abdominal pain, bloating and flatulence) and 
their composite sum have all been significantly improved with probiotics (Hoveyda et al. 
2009). 
From the microbiological point of view, it is of interest to see whether the symptom 
improvement during the intervention is linked to alteration within the GI microbiota – 
putatively to a state that better resembles that of healthy-like control subjects. If no change 
in the microbiota is seen in a specific study, this doesn’t necessarily mean there hasn’t been 
one as the methodology used may have missed the targets of interest. This has been the case 
for a multispecies supplement intervention trial with L. rhamnosus GG, L. rhamnosus LC705, 
B. breve Bb99 and P. freudenreichii ssp. shermanii JS (Kajander et al, 2005), first assessed by 
qPCR assays targeting known GI bacteria (Kajander et al, 2007) and thereafter by targeting 
IBS associated phylotypes (Lyra et al, 2010). The analyses of 300 known GI bacteria showed 
no alterations due to the intervention (Kajander et al, 2007), but a vast number of phylotypes 
may have been missed with analyses restricted by primer target selection, whereas in the 
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latter study, when the same samples were screened with qPCR assays targeting specifically 
IBS associated phylotypes (Lyra et al, 2010), alterations towards levels previously measured 
in controls devoid of GI symptoms (Lyra et al, 2009) were measured. 
Nobaek and co-workers (2000) have analysed abundances of Enterobacteriacea, sulphate-
reducing bacteria and Enterococci in IBS subjects consuming a rose-hip drink with 
Lactobacillus plantarum (DSM 9843). No alterations were detected in the probiotic group, but 
the probiotic strain was detected in faecal and rectal mucosal samples (Nobaek et al, 2000). 
Here again, the analysis method covered only a minor portion of the entire microbiota. 
In addition to affecting the bacterial levels and the stability of the GI microbiota, the relief of 
bloating and distention with probiotics may be linked to an effect on microbial metabolism 
(Schmulson & Chang, 2011). 
7. Conclusion 
Dysbiosis of the intestinal microbiota in IBS has been detected on several levels: the overall 
community appears to be less diverse with more variation between individuals and over 
time. These phenomena may reduce the resilience of the microbiota to external stressors, 
and both trigger and sustain functional aberrations in the gut. In addition to overall 
dysbiosis, specific bacterial groups are either elevated (Lactobacillus, Veillonella, 
Ruminococcus, Enterobacteria, aerobes as a group, S. aureus) or reduced (Bifidobactrium, B. 
catenulatum, Bacteroides) in IBS, but with the exception of bifidobacteria, the available data is 
not yet conclusive. Ruminococcal phylotypes have been associated specifically with IBS and 
also with inflammatory states in the intestinal tract in several studies and certainly deserve 
more attention. The analytical methodologies available for studying the GI microbiota have 
developed immensely in the past decade and the discovery of efficient microbial signature 
based diagnostic and therapeutic methods even for such a heterogeneous and subjectively 
defined patient group as IBS can be expected in the near future. 
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